Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 2, 2001, Pages 688-695

  Huang, Peng ^a   Kehner, George B ^a   Cowan, Alan ^a   Liu Chen, Lee Yuan ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DELTA OPIATE RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NOCICEPTIN RECEPTOR; NORBUPRENORPHINE; OPIATE AGONIST; PARTIAL AGONIST; SULFUR 35; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; GENETIC TRANSFECTION; MOUSE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; WRITHING TEST;

ACETIC ACID; ADENYLATE CYCLASE; ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; CELL MEMBRANE; CHO CELLS; CRICETINAE; FORSKOLIN; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MICE; PAIN MEASUREMENT; RECEPTORS, OPIOID;

EID: 0035028389     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Relationship between binding affinity and functional activity of nociceptin/orphanin FQ
2. Differential down- and up-regulation of rat brain opioid receptor types and sub-types by buprenorphine
3. Buprenorphine differentially alters opioid receptor adaptation in rat brain regions
4. Differential opioid agonist regulation of the mouse mu opioid receptor
5. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor
6. Antinociceptive actions of morphine and buprenorphine given intrathecally in the conscious rat
7. Characterization of irreversible binding of β-funaltrexamine to the cloned rat μ opioid receptor
8. Molecular cloning and functional expression of a μ-opioid receptor from rat brain
9. 50) of an enzymatic reaction
10. 63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces
11. D-2 dopamine receptor-mediated inhibition of adenylate cyclase activity in the intermediate lobe of the rat pituitary gland requires guanosine 5′-triphosphate
12. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent
13. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions
14. Cloning of a delta opioid receptor by functional expression
15. Pharmacokinetics of morphine and its surrogates. X. Analyses and pharmacokinetics of buprenorphine in dogs
16. Characterization of nociceptin hyperalgesia and allodynia in conscious mice
17. Antagonistic effects of [Nphe1]nociceptin(1-13)NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese hamster ovary cells stably expressing the recombinant human nociceptin receptor
18. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors
19. Antinociceptive effect of buprenorphine in mu1-opioid receptor deficient CXBK mice
20. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine
21. Buprenorphine has potent kappa opioid receptor antagonist activity
22. Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice
23. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors
24. Clinical pharmacology of buprenorphine in relation to its use as an analgesic
25. A practical computer based approach to the analysis of radioligand binding experiments
26. 1 receptor
27. Orphanin FQ is a functional anti-opioid peptide
28. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ
29. Kappa antagonist properties of buprenorphine in the shock titration procedure
30. Reinforcing effects, discriminative stimulus effects and physical dependence liability of buprenorphine
31. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine
32. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling
33. Quantitative determination of buprenorphine and its active metabolite, norbuprenorphine, in human plasma by gas chromatography-chemical ionization mass spectrometry
34. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia
35. Biphasic dose response curve to buprenorphine in the rat tail flick assay: Effect of naloxone pretreatment
36. Orphanin FQ: A neuropeptide that activates an opioid-like G protein-coupled receptor
37. 35S]-GTP-gamma-S functional binding assay
38. Buprenorphine: Differential interaction with opiate receptor subtypes in vivo
39. 35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus
40. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications
41. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells
42. Mechanism behind the bell-shaped dose-response curve of buprenorphine (BN) in rats: Antagonism by norbuprenorphine (NBN)
43. Buprenorphine and morphine cause antinociception by different transduction mechanisms
44. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay
45. Behavioral pharmacology of buprenorphine: Issues relevant to its potential in treating drug abuse
46. Mu-opioid receptor phosphorylation, desensitization, and ligand efficacy
47. Cloning of a human κ opioid receptor from the brain
48. 35S]GTPγ S binding to membranes: Determination of potencies and efficacies of ligands